Safety and efficacy evaluation of pertuzumab in patients with solid tumors

BACKGROUND: The development of targeted therapies benefits patients with certain markers in the treatment of breast cancer. Pertuzumab is a novel humanized monoclonal antibody that blocks human epidermal growth factor receptor 2 (HER2) dimerization. The Food and Drug Administration has approved pert...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Chenjing, Ling, Wenwu, Zhang, Jing, Gao, Hui, Shen, Kai, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440139/
https://www.ncbi.nlm.nih.gov/pubmed/28514302
http://dx.doi.org/10.1097/MD.0000000000006870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440139/
https://www.ncbi.nlm.nih.gov/pubmed/28514302
http://dx.doi.org/10.1097/MD.0000000000006870

Ejemplares similares